东阳光药三靶点 1 类新药启动临床

Insight数据库08-04

8 月 4 日，药物临床试验登记与信息公示平台官网显示，东阳光药登记了一项HEC-007 注射液的 I 期临床试验。公开资料显示，这是该药首次启动临床。截图来源：药物临床试验登记与信息公示平台官网这是一项单中心、随机、双盲、安慰剂对照研究，旨在评价 HEC-007 注射液在健康受试者中单次给药和在超重或肥胖受试者中多次给药的安全性、耐受性、药代动力学及药效学。主要终点包括安全性：不良事件、实验室...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2556802065?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-04 16:58","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2556802065","market":"hk","top_or_hot":-1,"title":"东阳光药三靶点 1 类新药启动临床","media":"Insight数据库","content":"<div>\n<p>8 月 4 日，药物临床试验登记与信息公示平台官网显示，东阳光药登记了一项HEC-007 注射液的 I 期临床试验。公开资料显示，这是该药首次启动临床。截图来源：药物临床试验登记与信息公示平台官网这是一项单中心、随机、双盲、安慰剂对照研究，旨在评价 HEC-007 注射液在健康受试者中单次给药和在超重或肥胖受试者中多次给药的安全性、耐受性、药代动力学及药效学。主要终点包括安全性：不良事件、实验室...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804173454a474277f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>东阳光药三靶点 1 类新药启动临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n东阳光药三靶点 1 类新药启动临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-04 16:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804173454a474277f&s=b><strong>Insight数据库</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8 月 4 日，药物临床试验登记与信息公示平台官网显示，东阳光药登记了一项HEC-007 注射液的 I 期临床试验。公开资料显示，这是该药首次启动临床。截图来源：药物临床试验登记与信息公示平台官网这是一项单中心、随机、双盲、安慰剂对照研究，旨在评价 HEC-007 注射液在健康受试者中单次给药和在超重或肥胖受试者中多次给药的安全性、耐受性、药代动力学及药效学。主要终点包括安全性：不良事件、实验室...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804173454a474277f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01558","symbol_name":"东阳光长江药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804173454a474277f&s=b","article_id":"2556802065","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804173454a474277f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2556802065","pubTimestamp":1754297911,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8 月 4 日，药物临床试验登记与信息公示平台官网显示，东阳光药登记了一项HEC-007 注射液的 I 期临床试验。公开资料显示，这是该药首次启动临床。4 月 24 日，该药获得 CDE 批准，拟开展2 型糖尿病以及超重或肥胖两项适应症的临床试验。Insight 数据库显示，目前全球范围内尚无 GLP-1/GCG/GIP 三靶点新药获批上市，进度最快的是礼来瑞他鲁肽，已进入 III 期临床阶段。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01558":"东阳光长江药业","BK1515":"抗疫概念","BK1191":"制药"},"translate_title":"HEC Pharmaceutical's three-target class 1 new drugs start clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01558":0.9},"content_text":"8 月 4 日，药物临床试验登记与信息公示平台官网显示，东阳光药登记了一项HEC-007 注射液的 I 期临床试验。公开资料显示，这是该药首次启动临床。截图来源：药物临床试验登记与信息公示平台官网这是一项单中心、随机、双盲、安慰剂对照研究，旨在评价 HEC-007 注射液在健康受试者中单次给药和在超重或肥胖受试者中多次给药的安全性、耐受性、药代动力学及药效学。主要终点包括安全性：不良事件、实验室检查、心电图检查、生命体征、体格检查等、HEC-007 注射液单次及多次给药的 PK 参数（Cmax、Tmax、AUC0-t、AUC0-∞、t1/2、CL/F 等）以及PD 指标（体重、腰围、腰臀比、空腹血糖、空腹胰岛素、空腹 C 肽、空腹胰高血糖素、空腹血脂、脂联素、HOMA-IR、血压、血尿酸等）。HEC-007 注射液是广东东阳光药业股份有限公司和东莞市东阳光生物药研发有限公司自主研发的 1 类创新药，是一种脂肪酸侧链修饰GLP-1/GCG/GIP 三靶点多肽新药，通过作用于胰高血糖素（GCG）受体、胰高血糖素样肽（GLP-1）受体与葡萄糖依赖性促胰岛素多肽（GIP）受体，协同各自对控糖与减重的生理作用，有望带来更佳的减重、降糖及其他伴随疾病的治疗效果。4 月 24 日，该药获得 CDE 批准，拟开展2 型糖尿病以及超重或肥胖两项适应症的临床试验。Insight 数据库显示，目前全球范围内尚无 GLP-1/GCG/GIP 三靶点新药获批上市，进度最快的是礼来瑞他鲁肽，已进入 III 期临床阶段。截图来源：Insight 数据库封面来源：企业 Logo","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2556802065","isCrawlerRequest":true}